Apr 11, 2019 (AB Digital via COMTEX) — Viral Vector Manufacturing Market – Overview
Viral vector manufacturing refers to the production of a carrier called a vector which is genetically engineered to deliver the gene because they can deliver the new gene by infecting the cell. Considered as a drug substance, viral vectors are used in gene therapy and vaccinology (vaccines). In the case of cell therapies, the scrutiny for testing for adventitious agents is high.
Viruses that are often used as vectors include retroviruses that integrate their genetic material including the new gene in the human cell, and adenoviruses, that introduce their DNA into the nucleus of the cell without letting the DNA to integrate into a chromosome. These viruses are modified so they can’t cause disease when used in people.
Gene therapy has seen various clinical advancement, and along with it, the viral vector manufacturing market is growing pervasively. Gene therapy is one of the most preferred treatment options for a number of chronic diseases. Over the past few years, the viral vector manufacturing market is growing rapidly mainly due to the growing prevalence of devastating neurodegenerative diseases including Parkinson’s, Alzheimer’s, and ALS.
Request Free Sample Copy at https://www.marketresearchfuture.com/sample_request/6890
Acknowledging the exponential accruals, the market is witnessing currently, Market Research Future (MRFR) in its recently published study report asserts that the global viral vector manufacturing market will garner a value of USD 319 MN by 2023, registering a whopping CAGR of approx. 22.65% throughout the forecast period (2018-2023).
The increasing number of clinical trials and the growing necessity for an effective mode of disease treatment are some of the factors fostering the growth of the market. Additional factors having a synergistic effect on the growth of the viral vector manufacturing market include the increasing number of technological advancements, a growing number of ambulatory services, and government initiatives.
On the flip side, factors such as the high cost of gene therapies and possible mutagenesis alongside the strict government regulation and time-consuming approval process are expected to impede market growth.
Some of the key players in the global viral vector manufacturing market are FinVector Vision Therapies, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., and Kaneka Eurogentec S.A.
The global viral vector manufacturing market has been segmented into type, disease, application, and end-user.
The market, on the basis of type, has been segmented retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors.
The market, by retroviral vectors, has been further segmented into lentiviral vectors and gamma-retroviral vectors.
The market, by disease, has been segmented into cancer, genetic disorders, infectious diseases, and others.
The market, by application, has been segmented into gene therapy and vaccinology.
The market, by end-user, has been segmented into pharmaceutical and biotechnology companies, research institutes, and others. The market, by pharmaceutical and biotechnology companies, is expected to hold the largest share in the market owing to the increasing demand for therapies, whereas the research institutes segment is projected to be the fastest growing segment due to growing awareness and specificity of viral vectors in treating the diseases.
The Americas is projected to dominate the global viral vector manufacturing market due to a well-developed healthcare sector and rising prevalence of autoimmune and chronic diseases. According to a study published by Partnership to Fight Chronic Disease (PFCD) in 2016, 191 million people in America had at least 1 chronic disease, whereas 75 million had 2 or more chronic diseases in the year 2015. Europe is expected to hold the second largest position in the global viral vector manufacturing market. The market growth in this region is attributed to the availability of funds for research and increasing healthcare expenditure. According to the European Commission, in 2016 the total expenditure of the governments of the European Union on health amounted to 7.1% of GDP. Also, according to National Institute of Health Funding (NIHR) in the year 2016, a funding of Euro 928 million was announced for new NIHR Biomedical Research Centres (BRC) and NIHR Clinical Research Facilities (CRF) for 5 years starting from April 2017.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies. On the other hand, the Middle East and Africa has the least share of the market.
Get Full Report with Niche Segments and Top Players at https://www.marketresearchfuture.com/reports/viral-vector-manufacturing-market-6890
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar